Brian Gloss has been a postdoctoral researcher in the Genome Informatics research lab at the Garvan Institute under A/Prof Marcel Dinger since 2013. His research interests revolve around unravelling transcriptional complexity in health and disease.
Brian is involved in a number of collaborative projects world-wide using existing and emerging transcriptomic technologies to answer key questions in normal development and disease processes.
He currently holds a Cancer Institute of NSW early career fellowship and a conjoint lecturer position at UNSW.
Brian has published eight papers in the last five years including three first and two second author publications. He also holds an international patent for a novel method of using epigenetic marks for diagnosing cancer. In 2012, he received his PhD for work on the whole genome identification and characterisation of novel epigenetically silenced genes in ovarian cancer.
In the NewsSlowing down the immune system when in overdrive - Feb 11, 2014
Potential for earlier diagnosis of ovarian cancer - Jan 24, 2012
Awards and Honours
2013: Ian Potter Foundation Travel Grant: $3,000
2012 Lorne Genome Best Student Presentation: $500
2010: Biomarkers Conference, Best Student Presentation: $300
2010: UNSW Postgraduate Research Support Scheme Travel Award: $3,000
2009: QANTAS Travel Award: $200
2009: ASMR Medical Research Week, Best Student Presentation: $500
2009-2011: Cancer Institute Research Scholar Award: $75,000
2008-2011: Australian Postgraduate Award: $87,000
2008-2011: Garvan Institute Top-Up Award: $24,500
2004 - Bachelor of Medical Research (Honours 1), University of Sydney - Australia
GLOSS, Brian, O'BRIEN, Philippa, CLARK, Susan,. METHOD OF DIAGNOSING CANCER. 2012. WO Patent 2,012,142,656
Rogers S, Gloss BS, Lee CS, Sergio CM, Dinger ME, Musgrove EA, Burgess A, Caldon CE. (2015) Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Div. 2015 Feb 19;10:1.
Quek XC, Thomson DW, Maag JL, Bartonicek N, Signal B, Clark MB, Gloss BS, Dinger ME. (2015) lncRNAdb v2.0: expanding the reference database for functional long noncoding RNAs. Nucleic Acids Res. 2015 Jan;43(Database issue):D168-73
Vogelzang, Alexis, McGuire, Helen M, Liu, Sue M, Gloss, Brian, Mercado, Karessa, Earls, Peter, Dinger, Marcel E, Batten, Marcel, Sprent, Jonathan, King, Cecile,. IL-21 Contributes to Fatal Inflammatory Disease in the Absence of Foxp3+ T Regulatory Cells. The Journal of Immunology. 1302285. 2014.
Gloss, Brian, Moran-Jones, Kim, Lin, Vita, Gonzalez, Maria, Scurry, James, Hacker, Neville F, Sutherland, Robert L, Clark, Susan J, Samimi, Goli,. ZNF300P1 Encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Molecular cancer. 13. 1. 3. 2014.
Warton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mangs H, Nair SS, Hacker NF, Sutherland RL, Clark SJ, Samimi G. (2014) Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. BMC Genomics. 2014 Jun 15;15:476.
Gloss, Brian S, Patterson, Kate I, Barton, Caroline A, Gonzalez, Maria, Scurry, James P, Hacker, Neville F, Sutherland, Robert L, O’Brien, Philippa M, Clark, Susan J,. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer letters. 318. 1. 76-85. 2012.
Gloss, Brian S, Samimi, Goli,. Epigenetic biomarkers in epithelial ovarian cancer. Cancer letters. 342. 2. 257-263. 2014.
Montavon, Celine, Gloss, Brian S, Warton, Kristina, Barton, Caroline A, Statham, Aaron L, Scurry, James P, Tabor, Bruce, Nguyen, Tuan V, Qu, Wenja, Samimi, Goli,. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecologic oncology. 124. 3. 582-588. 2012.
Barton, CA, Gloss, BS, Qu, W, Statham, AL, Hacker, NF, Sutherland, RL, Clark, SJ, O'Brien, PM,. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival. British journal of cancer. 102. 1. 87-96. 2010.
Byrne, Jennifer A, Maleki, Sanaz, Hardy, Jayne R, Gloss, Brian S, Murali, Rajmohan, Scurry, James P, Fanayan, Susan, Emmanuel, Catherine, Hacker, Neville F, Sutherland, Robert L,. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC cancer. 10. 1. 497. 2010.
Milone, Michael C, Fish, Jonathan D, Carpenito, Carmine, Carroll, Richard G, Binder, Gwendolyn K, Teachey, David, Samanta, Minu, Lakhal, Mehdi, Gloss, Brian, Danet-Desnoyers, Gwenn,. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy. 17. 8. 1453-1464. 2009.
O'Brien, PM, Davies, MJ, Scurry, JP, Smith, AN, Barton, CA, Henderson, MJ, Saunders, DN, Gloss, BS, Patterson, KI, Clancy, JL,. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British journal of cancer. 98. 6. 1085-1093. 2008.
Dr Brian GlossEmail: Click here to Email